Literature DB >> 29134853

Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience.

Diego Castini1, Simone Persampieri2, Sara Cazzaniga2, Giulia Ferrante2, Marco Centola2, Stefano Lucreziotti2, Diego Salerno-Uriarte2, Carlo Sponzilli2, Stefano Carugo2.   

Abstract

BACKGROUND: With this study, we sought to identify patient characteristics associated with clopidogrel prescription and its relationship with in-hospital adverse events in an unselected cohort of ACSs patients.
MATERIALS AND METHODS: We studied all consecutive patients admitted at our institution for ACSs from 2012 to 2014. Patients were divided into two groups based on clopidogrel or novel P2Y12 inhibitors (prasugrel or ticagrelor) prescription and the relationship between clopidogrel use and patient clinical characteristics and in-hospital adverse events was evaluated using logistic regression analysis.
RESULTS: The population median age was 68 years (57-77 year) and clopidogrel was prescribed in 230 patients (46%). Patients characteristics associated with clopidogrel prescription were older age, female sex, non-ST-elevation ACS diagnosis, the presence of diabetes mellitus and anemia, worse renal and left ventricular functions and a higher Killip class. Patients on clopidogrel demonstrated a significantly higher incidence of in-hospital mortality (4.8%) than prasugrel and ticagrelor-treated patients (0.4%), while a nonstatistically significant trend emerged considering bleeding events. However, on multivariable logistic regression analysis female sex, the presence of anemia and Killip class were the only variables independently associated with in-hospital death.
CONCLUSION: Patients treated with clopidogrel showed a higher in-hospital mortality. However, clinical variables associated with its use identify a population at high risk for adverse events and this seems to play a major role for the higher in-hospital mortality observed in clopidogrel-treated patients.

Entities:  

Keywords:  acute coronary syndromes; clopidogrel; dual antiplatelet therapy; prasugrel; ticagrelor

Mesh:

Substances:

Year:  2017        PMID: 29134853      PMCID: PMC5933677          DOI: 10.1177/1753944717738911

Source DB:  PubMed          Journal:  Ther Adv Cardiovasc Dis        ISSN: 1753-9447


  28 in total

Review 1.  Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology.

Authors:  Carlo Patrono; Fedor Bachmann; Colin Baigent; Christopher Bode; Raffaele De Caterina; Bernard Charbonnier; Desmond Fitzgerald; Jack Hirsh; Steen Husted; Jan Kvasnicka; Gilles Montalescot; Luis Alberto García Rodríguez; Freek Verheugt; Jozef Vermylen; Lars Wallentin; Silvia G Priori; Maria Angeles Alonso Garcia; Jean Jacques Blanc; Andrzej Budaj; Martin Cowie; Veronica Dean; Jaap Deckers; Enrique Fernández Burgos; John Lekakis; Bertil Lindahl; Gianfranco Mazzotta; João Morais; Ali Oto; Otto A Smiseth; João Morais; Jaap Deckers; Rafael Ferreira; Gianfranco Mazzotta; Philippe Gabriel Steg; Frederico Teixeira; Robert Wilcox
Journal:  Eur Heart J       Date:  2004-01       Impact factor: 29.983

2.  Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.

Authors:  M B Yudi; D J Clark; O Farouque; D Eccleston; N Andrianopoulos; S J Duffy; A Brennan; J Lefkovits; J Ramchand; T Yip; E Oqueli; C M Reid; A E Ajani
Journal:  Intern Med J       Date:  2016-05       Impact factor: 2.048

3.  Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.

Authors:  Roxana Mehran; Sunil V Rao; Deepak L Bhatt; C Michael Gibson; Adriano Caixeta; John Eikelboom; Sanjay Kaul; Stephen D Wiviott; Venu Menon; Eugenia Nikolsky; Victor Serebruany; Marco Valgimigli; Pascal Vranckx; David Taggart; Joseph F Sabik; Donald E Cutlip; Mitchell W Krucoff; E Magnus Ohman; Philippe Gabriel Steg; Harvey White
Journal:  Circulation       Date:  2011-06-14       Impact factor: 29.690

4.  Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.

Authors:  Dean J Kereiakes; Robert W Yeh; Joseph M Massaro; Priscilla Driscoll-Shempp; Donald E Cutlip; P Gabriel Steg; Anthony H Gershlick; Harald Darius; Ian T Meredith; John Ormiston; Jean Francois Tanguay; Stephan Windecker; Kirk N Garratt; David E Kandzari; David P Lee; Daniel I Simon; Adrian Corneliu Iancu; Jaroslaw Trebacz; Laura Mauri
Journal:  JAMA       Date:  2015-03-17       Impact factor: 56.272

5.  MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.

Authors:  Peter Clemmensen; Niccolò Grieco; Hüseyin Ince; Nicolas Danchin; Jochen Goedicke; Yvonne Ramos; Josef Schmitt; Patrick Goldstein
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2014-09-02

6.  Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.

Authors:  Steen Husted; Stefan James; Richard C Becker; Jay Horrow; Hugo Katus; Robert F Storey; Christopher P Cannon; Magda Heras; Renato D Lopes; Joao Morais; Kenneth W Mahaffey; Richard G Bach; Daniel Wojdyla; Lars Wallentin
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-09-01

7.  Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries.

Authors:  Nicolas Danchin; Maddalena Lettino; Uwe Zeymer; Petr Widimsky; Alfredo Bardaji; Jose A Barrabes; Angel Cequier; Marc J Claeys; Leonardo De Luca; Jakob Dörler; David Erlinge; Paul Erne; Patrick Goldstein; Sasha M Koul; Gilles Lemesle; Thomas F Lüscher; Christian M Matter; Gilles Montalescot; Dragana Radovanovic; Jose Lopez Sendón; Petr Tousek; Franz Weidinger; Clive F M Weston; Azfar Zaman; Pontus Andell; Jin Li; J Wouter Jukema
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2016-01-27

8.  Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health.

Authors:  Keun-Ho Park; Myung Ho Jeong; Youngkeun Ahn; Tae Hoon Ahn; Ki Bae Seung; Dong Joo Oh; Dong-Joo Choi; Hyo-Soo Kim; Hyeon Cheol Gwon; In Whan Seong; Kyung Kuk Hwang; Shung Chull Chae; Kwon-Bae Kim; Young Jo Kim; Kwang Soo Cha; Seok Kyu Oh; Jei Keon Chae
Journal:  Int J Cardiol       Date:  2016-04-14       Impact factor: 4.164

9.  Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).

Authors:  Dimitrios Alexopoulos; John A Goudevenos; Ioanna Xanthopoulou; Spyridon Deftereos; George Sitafidis; Ioannis Kanakakis; Michalis Hamilos; Haralambos Parissis; Ioannis V Ntalas; Christos Angelidis; Stylianos Petousis; Manolis Vavuranakis; George Hahalis; Christodoulos Stefanadis
Journal:  Int J Cardiol       Date:  2013-08-15       Impact factor: 4.164

10.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).

Authors:  Marco Roffi; Carlo Patrono; Jean-Philippe Collet; Christian Mueller; Marco Valgimigli; Felicita Andreotti; Jeroen J Bax; Michael A Borger; Carlos Brotons; Derek P Chew; Baris Gencer; Gerd Hasenfuss; Keld Kjeldsen; Patrizio Lancellotti; Ulf Landmesser; Julinda Mehilli; Debabrata Mukherjee; Robert F Storey; Stephan Windecker
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

View more
  2 in total

1.  Anemia in patients with high-risk acute coronary syndromes admitted to Intensive Cardiac Care Units.

Authors:  Victòria Lorente; Jaime Aboal; Cosme Garcia; Jordi Sans-Roselló; Antonia Sambola; Rut Andrea; Carlos Tomás; Gil Bonet; David Viñas; Nabil El Ouaddi; Santiago Montero; Javier Cantalapiedra; Margarida Pujol; Isabel Hernández; María Pérez-Rodriguez; Isaac Llaó; José C Sánchez-Salado; Miquel Gual; Albert Ariza-Solé
Journal:  J Geriatr Cardiol       Date:  2020-01       Impact factor: 3.327

2.  Trends of prescribing adherence of antiplatelet agents in Hong Kong patients with acute coronary syndrome: a 10-year retrospective observational cohort study.

Authors:  Amy Sm Lam; Bryan Py Yan; Vivian Wy Lee
Journal:  BMJ Open       Date:  2020-12-03       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.